First Time Loading...
C

China National Accord Medicines Corp Ltd
SZSE:000028

Watchlist Manager
China National Accord Medicines Corp Ltd
SZSE:000028
Watchlist
Price: 38.6 CNY -0.97% Market Closed
Updated: May 21, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

47.6B
-6%
Assets
Growth Rates:
1 Year
+12%
3 Years
+20%
5 Years
+64%
7 Years
+123%
10 Years
+330%
30.2B
-11%
Liabilities
Growth Rates:
1 Year
+14%
3 Years
+18%
5 Years
+74%
7 Years
+134%
10 Years
+242%
17.4B
+3%
Equity
Growth Rates:
1 Year
+8%
3 Years
+25%
5 Years
+50%
7 Years
+106%
10 Years
+676%

Balance Sheet Decomposition
China National Accord Medicines Corp Ltd

47.6B
Assets
30.2B
Liabilities
47.6B
Assets
30.2B
Liabilities
Current Assets 36.4B
Cash & Short-Term Investments 5.8B
Receivables 21.3B
Other Current Assets 9.3B
Non-Current Assets 11.2B
Long-Term Investments 3.1B
PP&E 3.7B
Intangibles 3.4B
Other Non-Current Assets 1B
Current Liabilities 24.3B
Accounts Payable 9.6B
Accrued Liabilities 743.1m
Short-Term Debt 11.3B
Other Current Liabilities 2.7B
Non-Current Liabilities 5.8B
Long-Term Debt 1.5B
Other Non-Current Liabilities 4.4B

Balance Sheet
China National Accord Medicines Corp Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
868
2 655
3 155
3 677
7 639
8 443
5 405
4 734
5 442
5 835
Cash
0
3
6
6
6
5
7
4 734
5 442
5 835
Cash Equivalents
868
2 652
3 149
3 671
7 633
8 438
5 398
0
0
0
Total Receivables
7 706
9 291
9 692
9 830
11 426
12 556
16 492
18 575
17 004
21 254
Accounts Receivables
7 018
7 827
7 654
7 589
9 337
10 713
13 815
15 994
13 783
18 171
Other Receivables
688
1 464
2 038
2 241
2 089
1 843
2 677
2 581
3 221
3 083
Inventory
2 322
4 165
4 049
3 782
4 389
5 063
6 285
7 622
7 836
7 989
Other Current Assets
96
641
792
1 033
1 042
833
1 080
918
1 426
1 292
Total Current Assets
10 992
16 752
17 689
18 321
24 496
26 896
29 262
31 848
31 708
36 370
PP&E Net
1 139
1 620
561
594
655
2 756
3 283
3 534
3 449
3 741
PP&E Gross
1 139
1 620
561
594
655
2 756
3 283
3 534
3 449
3 741
Accumulated Depreciation
583
800
420
466
531
1 295
2 034
2 613
3 088
3 624
Intangible Assets
150
415
320
326
319
375
734
670
648
616
Goodwill
79
825
824
831
834
1 010
2 747
2 776
2 750
2 747
Note Receivable
0
0
0
0
0
0
7
17
14
16
Long-Term Investments
231
356
1 593
1 878
2 179
2 500
2 635
2 772
2 908
3 059
Other Long-Term Assets
237
346
329
394
448
492
926
1 167
1 139
1 023
Other Assets
79
825
824
831
834
1 010
2 747
2 776
2 750
2 747
Total Assets
12 829
N/A
20 313
+58%
21 317
+5%
22 344
+5%
28 930
+29%
34 029
+18%
39 595
+16%
42 784
+8%
42 616
0%
47 571
+12%
Liabilities
Accounts Payable
3 989
6 012
6 702
6 144
6 469
6 704
7 697
9 058
8 208
9 574
Accrued Liabilities
202
323
294
340
366
404
555
781
998
743
Short-Term Debt
2 986
4 162
3 919
4 325
6 047
7 092
9 148
10 151
9 157
11 285
Current Portion of Long-Term Debt
4
8
36
5
6
612
749
848
913
1 019
Other Current Liabilities
507
1 518
1 184
1 315
1 871
2 152
2 108
1 541
1 751
1 717
Total Current Liabilities
7 688
12 022
12 136
12 130
14 758
16 964
20 258
22 379
21 028
24 338
Long-Term Debt
40
86
15
41
35
1 208
1 335
1 447
1 345
1 452
Deferred Income Tax
24
84
77
72
68
118
206
176
156
146
Minority Interest
87
519
465
531
2 287
2 663
2 940
3 097
3 319
3 563
Other Liabilities
226
250
172
173
164
164
908
759
642
657
Total Liabilities
8 064
N/A
12 960
+61%
12 864
-1%
12 947
+1%
17 312
+34%
21 118
+22%
25 646
+21%
27 859
+9%
26 490
-5%
30 156
+14%
Equity
Common Stock
363
363
363
428
428
428
428
428
428
557
Retained Earnings
2 538
3 793
4 872
5 787
6 869
7 966
9 109
10 103
11 333
12 590
Additional Paid In Capital
1 864
3 198
3 153
3 181
4 321
4 471
4 373
4 372
4 357
4 261
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
22
8
8
Other Equity
0
0
65
0
0
46
38
0
0
0
Total Equity
4 765
N/A
7 353
+54%
8 452
+15%
9 397
+11%
11 618
+24%
12 911
+11%
13 948
+8%
14 925
+7%
16 126
+8%
17 415
+8%
Total Liabilities & Equity
12 829
N/A
20 313
+58%
21 317
+5%
22 344
+5%
28 930
+29%
34 029
+18%
39 595
+16%
42 784
+8%
42 616
0%
47 571
+12%
Shares Outstanding
Common Shares Outstanding
363
363
363
428
428
428
428
557
557
557

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 139,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.